NSAIDs and gastrointestinal complications: new clinical challenges

被引：17

作者：

Abraham, NS ^{[1
]}

Graham, DY ^{[1
]}

机构：

[1] Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX 77030 USA

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2005年 / 6卷 / 15期

关键词：

coxib; COX-2; inhibitor; NSAIDs; peptic ulcer; upper gastrointestinal tract bleeding;

D O I：

10.1517/14656566.6.15.2681

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The use of NSAIDs is associated with significant risk of upper gastrointestinal ulcer, bleeding, perforation and stricture. NSAIDs vary in their analgesic and anti-inflammatory properties; choice of NSAID, dosage and duration are the cornerstone of rationale therapy. Proton pump inhibitors are widely used to reduce the risk of serious events, despite the paucity of data that indicates that they are effective for this indication. The existing recommendations for prevention of gastrointestinal toxicity are reviewed in this article, in light of new clinical challenges posed by the emerging data regarding competing cardiovascular risk. Strategies are proposed for common clinical prescribing dilemmas, new clinical risk groups are identified and preventative strategies for these special populations are recommended.

引用

页码：2681 / 2689

页数：9

共 75 条

[1] Comparison of the upper gastrointestinal safety of Arthrotec® 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers [J].

Agrawal, NM ;

Caldwell, J ;

Kivitz, AJ ;

Weaver, AL ;

Bocanegra, TS ;

Ball, J ;

Dhadda, S ;

Hurley, S ;

Hancock, L .

CLINICAL THERAPEUTICS, 1999, 21 (04) :659-674

[2]

Altman RD, 2000, ARTHRITIS RHEUM-US, V43, P1905

[3]

Bocanegra TS, 1998, J RHEUMATOL, V25, P1602

[4] Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].

Bombardier, C ;

Laine, L ;

Reicin, A ;

Shapiro, D ;

Burgos-Vargas, R ;

Davis, B ;

Day, R ;

Ferraz, MB ;

Hawkey, CJ ;

Hochberg, MC ;

Kvien, TK ;

Schnitzer, TJ ;

Weaver, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528

[5] Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications - review and recommendations based on risk assessment [J].

Chan, FKL ;

Graham, DY .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (10) :1051-1061

[6] Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen [J].

Chan, FKL ;

Chung, SCS ;

Suen, BY ;

Lee, YT ;

Leung, WK ;

Leung, VKS ;

Wu, JCY ;

Lau, JYW ;

Hui, Y ;

Lai, MS ;

Chan, HLY ;

Sung, JJY .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (13) :967-973

[7] Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers [J].

Chan, FKL ;

Sung, JJY ;

Chung, SCS ;

To, KF ;

Yung, MY ;

Leung, VKS ;

Lee, YT ;

Chan, CSY ;

Li, EKM ;

Woo, J .

LANCET, 1997, 350 (9083) :975-979

[8] DOUBLE-BLIND EVALUATION OF SUPROFEN AND ASPIRIN IN THE TREATMENT OF PERIODONTAL PAIN [J].

COOPER, SA ;

WAGENBERG, B ;

ESKOW, R ;

ZISSU, J .

PHARMACOLOGY, 1983, 27 :23-30

[9] Over-the-counter pain reliever and aspirin use within a sample of long-term cyclooxygenase 2 users [J].

Cox, ER ;

Frisse, M ;

Behm, A ;

Fairman, KA .

ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (11) :1243-1246

[10] Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis [J].

Derry, S ;

Loke, YK .

BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7270) :1183-+

← 1 2 3 4 5 6 7 8 →